Pulst S
Neurol Genet. 2025; 11(1):e200225.
PMID: 39872677
PMC: 11772019.
DOI: 10.1212/NXG.0000000000200225.
Tian Y, Heinsinger N, Hu Y, Lim U, Wang Y, Fernandis A
PLoS One. 2024; 19(12):e0308428.
PMID: 39739690
PMC: 11687654.
DOI: 10.1371/journal.pone.0308428.
Costa R, Conceicao A, Matos C, Nobrega C
Cell Death Dis. 2024; 15(6):415.
PMID: 38877004
PMC: 11178924.
DOI: 10.1038/s41419-024-06812-5.
Paul S, Dansithong W, Gandelman M, Figueroa K, Scoles D, Pulst S
Neurol Genet. 2024; 10(2):e200144.
PMID: 38715656
PMC: 11073881.
DOI: 10.1212/NXG.0000000000200144.
Borrego-Hernandez D, Vazquez-Costa J, Dominguez-Rubio R, Exposito-Blazquez L, Aller E, Padro-Miquel A
Biomedicines. 2024; 12(2).
PMID: 38397958
PMC: 10886453.
DOI: 10.3390/biomedicines12020356.
ATXN2 is a target of N-terminal proteolysis.
Chitre M, Emery P
PLoS One. 2023; 18(12):e0296085.
PMID: 38128014
PMC: 10735043.
DOI: 10.1371/journal.pone.0296085.
Abnormal phase separation of biomacromolecules in human diseases.
Zhang S, Pei G, Li B, Li P, Lin Y
Acta Biochim Biophys Sin (Shanghai). 2023; 55(7):1133-1152.
PMID: 37475546
PMC: 10423695.
DOI: 10.3724/abbs.2023139.
Poly(A)-binding protein is an ataxin-2 chaperone that regulates biomolecular condensates.
Boeynaems S, Dorone Y, Zhuang Y, Shabardina V, Huang G, Marian A
Mol Cell. 2023; 83(12):2020-2034.e6.
PMID: 37295429
PMC: 10318123.
DOI: 10.1016/j.molcel.2023.05.025.
Pbp1 associates with Puf3 and promotes translation of its target mRNAs involved in mitochondrial biogenesis.
van de Poll F, Sutter B, Acoba M, Caballero D, Jahangiri S, Yang Y
PLoS Genet. 2023; 19(5):e1010774.
PMID: 37216416
PMC: 10237644.
DOI: 10.1371/journal.pgen.1010774.
TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2.
Bux J, Sen N, Klink I, Hauser S, Synofzik M, Schols L
Mol Neurobiol. 2023; 60(6):3553-3567.
PMID: 36894829
PMC: 10122633.
DOI: 10.1007/s12035-023-03294-y.
Hsc70-4 aggravates PolyQ-mediated neurodegeneration by modulating NF-κB mediated immune response in .
Rai S, Tapadia M
Front Mol Neurosci. 2022; 15:857257.
PMID: 36425218
PMC: 9678916.
DOI: 10.3389/fnmol.2022.857257.
Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2.
Kim G, Nakayama L, Blum J, Akiyama T, Boeynaems S, Chakraborty M
Cell Rep. 2022; 41(4):111508.
PMID: 36288714
PMC: 9664452.
DOI: 10.1016/j.celrep.2022.111508.
Mutant Ataxin-2 Expression in Aged Animals Aggravates Neuropathological Features Associated with Spinocerebellar Ataxia Type 2.
Afonso I, Lima P, Conceicao A, Matos C, Nobrega C
Int J Mol Sci. 2022; 23(19).
PMID: 36233198
PMC: 9569585.
DOI: 10.3390/ijms231911896.
Cognition in Trinucleotide Repeat Spinocerebellar Ataxias: A Review.
Agarwal A, Pankaj , Faruq M, Garg A, Srivastava A
Ann Indian Acad Neurol. 2022; 25(4):601-605.
PMID: 36211141
PMC: 9540958.
DOI: 10.4103/aian.aian_63_22.
A survey of protein interactions and posttranslational modifications that influence the polyglutamine diseases.
Johnson S, Tsou W, Prifti M, Harris A, Todi S
Front Mol Neurosci. 2022; 15:974167.
PMID: 36187346
PMC: 9515312.
DOI: 10.3389/fnmol.2022.974167.
A quantitative high-throughput screen identifies compounds that lower expression of the SCA2-and ALS-associated gene ATXN2.
Scoles D, Gandelman M, Paul S, Dexheimer T, Dansithong W, Figueroa K
J Biol Chem. 2022; 298(8):102228.
PMID: 35787375
PMC: 9356275.
DOI: 10.1016/j.jbc.2022.102228.
The Clinical and Polynucleotide Repeat Expansion Analysis of and in Patients With ALS From Mainland China.
Hou X, Li W, Liu P, Liu Z, Yuan Y, Ni J
Front Neurol. 2022; 13:811202.
PMID: 35599735
PMC: 9120572.
DOI: 10.3389/fneur.2022.811202.
Are variants modifying our understanding about neural pathogenesis, phenotypes, and diagnostic?.
Laffita-Mesa J, Paucar M, Svenningsson P
Neural Regen Res. 2022; 17(11):2445-2447.
PMID: 35535893
PMC: 9120687.
DOI: 10.4103/1673-5374.338996.
Molecular Mechanisms in Pentanucleotide Repeat Diseases.
Loureiro J, Castro A, Figueiredo A, Silveira I
Cells. 2022; 11(2).
PMID: 35053321
PMC: 8773600.
DOI: 10.3390/cells11020205.
Molecular and Clinical Implications of Variant Repeats in Myotonic Dystrophy Type 1.
Peric S, Pesovic J, Savic-Pavicevic D, Stojanovic V, Meola G
Int J Mol Sci. 2022; 23(1).
PMID: 35008780
PMC: 8745394.
DOI: 10.3390/ijms23010354.